292605-14-2
292605-14-2 structure
- Name: SB-3CT
- Chemical Name: 2-[(4-phenoxyphenyl)sulfonylmethyl]thiirane
- CAS Number: 292605-14-2
- Molecular Formula: C15H14O3S2
- Molecular Weight: 306.400
- Catalog: Biochemical Inhibitor Proteases MMP inhibitor
- Create Date: 2016-12-21 08:42:59
- Modify Date: 2024-01-02 11:07:15
-
SB-3CT is a potent and competitive inhibitor of matrix metalloproteinase (MMP-2) and MMP-9.
| Name | 2-[(4-phenoxyphenyl)sulfonylmethyl]thiirane |
|---|---|
| Synonyms |
2-[[(4-phenoxyphenyl)sulfonyl]methyl]-Thiirane
2-((4-phenoxyphenylsulfonyl)methyl)thiirane IN1250 2-{[(4-Phenoxyphenyl)sulfonyl]methyl}thiirane Thiirane, 2-[[(4-phenoxyphenyl)sulfonyl]methyl]- MMP-2/MMP-9 Inhibitor IV SB-3CT |
| Description | SB-3CT is a potent and competitive inhibitor of matrix metalloproteinase (MMP-2) and MMP-9. |
|---|---|
| Related Catalog | |
| Target |
MMP-2, MMP-9[1] |
| In Vitro | SB-3CT has shown efficacy in an animal model of severe traumatic brain injury (TBI). SB-3CT inhibits MMP-9 with an inhibition constant Ki of 400±15 nM[1]. Inhibition of PC3 tumor growth by SB-3CT could also be a direct consequence of reduced extracellular matrix degradation within the bone tissue by the tumor cells themselves and/or by osteoclasts. Indeed, SB-3CT treatment is associated with a reduced osteolytic response, indicating that SB-3CT helps to preserve bone integrity[2]. |
| In Vivo | Post-ischemic treatment with SB-3CT significantly diminishes brain damage and reduced infarct volume to about 20% of the total hemisphere. SB-3CT treatment ameliorates neurobehavioral outcomes, particularly in the motor and sensory functions[3]. |
| Cell Assay | PC3 cells are seeded in 35-mm dishes (5×104 cells/dish) in complete culture medium. The next day, the medium is replaced with complete medium supplemented with 1% DMSO alone (vehicle) or SB-3CT (final concentrations 0.1-50 μM) in 1%DMSO. At various times, the cells are harvested with trypsin and counted[2]. |
| Animal Admin | Adult male C57Bl/6 J mice, 6-9 weeks of age and weighing 20-28 g are divided into four groups: vehicle-treated group and SB-3CT-treated one with treatment for either one day or seven days after embolic MCA occlusion. SB-3CT (12.5 mg/mL) is freshly dissolved in 25% DMSO/65% PEG-200/10% water and filtered through an Acrodisc syringe filter with a 0.2 μm, 13-mm diameter sterile hydrophobic PTFE membrane. Mice are ip injected with 2 μL/gram body weight of this solution (equivalent to 25 mg/kg) 2 hours after embolic ischemia, followed by an additional dose at 4 hours. In repeated-dose treatment conditions, the same dose of SB-3CT is ip administered 2 and 4 hours after embolic ischemia, followed by once daily from post-ischemia day 1 to 6. Earlier work indicated that ip administration of SB-3CT does not alter mean arterial blood pressure, pH, PCO2, and PO2. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 501.4±46.0 °C at 760 mmHg |
| Melting Point | 101 °C |
| Molecular Formula | C15H14O3S2 |
| Molecular Weight | 306.400 |
| Flash Point | 257.1±29.0 °C |
| Exact Mass | 306.038422 |
| PSA | 77.05000 |
| LogP | 3.36 |
| Appearance | white to off-white |
| Vapour Pressure | 0.0±1.2 mmHg at 25°C |
| Index of Refraction | 1.628 |
| Storage condition | ?20°C |
| Water Solubility | DMSO: >20mg/mL |
